"GLP-1s are a welcome and important tool in helping people diagnosed with OSA to meet their weight challenges in order to achieve better health, but they are only one piece of the puzzle when it comes to OSA." For further insights into ResMed's perspective on the link between obesity and sleep health, the SURMOUNT-OSA trial and our dedication to sleep health, visit https://lnkd.in/geNgXHNN.
"ResMed has always done what’s best for patients, encouraging all patients to live healthier lives through sleep, diet and exercise. The recent SURMOUNT-OSA clinical trial results are good news for individuals with obesity and sleep apnea. GLP-1 medications will give physicians more options in how they treat patients; GLP-1s will likely be used concomitantly with positive airway pressure (PAP) therapy. " Our Chief Medical Officer, Carlos Nunez, takes a closer look at what the latest GLP-1 data could mean for those with OSA. https://lnkd.in/gKgdMjeT